-
2024-06-27
US FDA New Drug Application Approval of Ohtuvayre™ (ensifentrine) for the Maintenance Treatment of COPD
Nuance Pharma's global partner Verona Pharma plc (Nasdaq: VRNA), announces the US Food and Drug Administration ("FDA") approved Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patie
-
2023-06-28
Nuance Pharma's Partner Verona Pharma Submits New Drug Application to US FDA for Ensifentrine for the Maintenance Treatment of COPD
Nuance Pharma announces its partner, Verona Pharma plc (Nasdaq: VRNA), has submitted a New Drug Application ("NDA") to the US Food and Drug Administration ("FDA") for approval of ensifentrine fo
-
2023-04-25
优锐医药First-in-Class慢阻肺管线中国III期顺利启动，加速推进呼吸特药精耕
动脉网获悉，专注呼吸类创新药的生物医药公司：优锐医药，已经于2023年4月6日完成Ensifentrine ENHANCE - CHINAIII期临床试验的首例患者给药，适用于中国大陆区域慢性阻塞性肺疾病(COPD)疾病的维持治疗。
-
2023-04-06
Ensifentrine Completes Dosing of First Patient in ENHANCE - CHINA Phase III Trial for COPD
Nuance Pharma announces dosing of first patient in the ENHANCE - China Phase III Trial for the maintenance treatment of chronic obstructive pulmonary disease ("COPD") of its novel
-
2022-10-28
专访优锐医药：呼吸精品特药领域，如何打造现金“造血”教科书？
近日，动脉新医药访谈了优锐医药创始人兼CEO Mark Lotter先生。Mark Lotter曾是阿斯利康的首批来华高管，拥有超过20年的中国医疗行业市场经验。Mark Lotter与我们分享了优锐医药如何练就现金“造血”能力，并逐步成长为具有差异化的特药医疗公司。
-
2022-08-18
IND Approval for Ensifentrine Pivotal Clinical Trials for COPD in China
Nuance Pharma announces the Center for Drug Evaluation ("CDE") has approved its Investigational New Drug ("IND") application supporting its pivotal clinical trial of Ens
-
2022-07-26
Nuance Pharma announces the completion of dosing for all NTM-001 Phase 1 clinical study participants in HKU Clinical Trials Centre
Nuance Pharma announces the completion of dosing for all HNVs in the Phase I clinical study of its novel Ketorolac for IV infusion (NTM-001), a non-opioid analgesic drug co-developed with N
-
2022-01-06
Nuance Pharma acquires Sino Health to further strengthen its commercial capabilities and expand pipelines
Nuance Pharma announced an agreement with Sino Health Pharmaceutical Limited to fully acquire its 100-percent equity shares and its fully-owned subsidiaries Ying Lian Zhuhai and Ying Lian Germany.
Contact PR
